1 / 4

Contract Pharmaceutical Manufacturing Market Advancements to Watch Out For 2026

Pharmaceutical companies are now pushing hard to reduce overall manufacturing and research costs by outsourcing various processes related to research, development and manufacturing. <br>

rushi12
Download Presentation

Contract Pharmaceutical Manufacturing Market Advancements to Watch Out For 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Contract Pharmaceutical Manufacturing Market - Contract Pharmaceutical Manufacturing Market - Size, Share, Growth, Outlook, and Opportunity Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Analysis, 2018-2026 Pharmaceutical companies are now pushing hard to reduce overall manufacturing and research costs by outsourcing various processes related to research, development and manufacturing. Furthermore, patent expiration and generic drug competition, continue to fuel demand for pharmaceutical contract manufacturing organizations in the market. Rising number of Food and Drug Administration (FDA) approvals and clinical trials are supporting growth of biopharmaceutical industry, which in turn is fueling growth of the contract pharmaceutical manufacturing market. For instance, according to ClinicalTrials.gov, from September 2008 to October 2018, there were around 288,064 clinical trial studies registered. In addition, there is a significant increase over the past few years with registered clinical studies of 205,428, 233,234, and 262,429 in 2015, 2016, and 2017, respectively. Request Sample Copy of Research Report:https://www.coherentmarketinsights.com/insight/request-sample/2397 Growing Need to Outsource Small Molecules’ Manufacturing is expected to Augment Market Growth Demand for small molecules is considerably high compared to large molecules, owing to its various advantages in manufacturing and clinical trial studies. For instance, according to Cambrex Corporation, 2017 report, small molecules dominates in the pharmaceutical industry, having 34 small molecule new entities being approved in 2017, which is the highest number in the last decade, by the U.S. Food and Drug Administration (FDA). Furthermore, small molecules can be engineered to deliver strong therapeutic effect with small dose, below 10 mgs and even micrograms. Rising Demand for Generic Drugs is expected to Propel the Market Growth Development of generic drugs offer opportunities for manufacturers, as consumers’ demand for cost-effective pharmaceuticals is increasing. Patients being treated for chronic disease using

  2. generic drug are more likely to continue their drug therapy and have their prescriptions refilled than those using branded drugs. Moreover, the expiration of patents, emerging markets, increasing geriatric population, rising prevalence of chronic diseases, and the efforts of governments and healthcare service providers have contributed to the increased use and acceptance of generic drugs. This increasing demand for generic drugs is offering lucrative growth opportunity for contract pharmaceutical manufacturing organizations in the near future. Furthermore, adoption of novel manufacturing technologies, increased competition, and shrinking profit margins has compelled pharma companies to outsource its production processes and R&D of the drugs to contract research organization (CRO) and contract manufacturing organizations (CMO), to stay competitive in the market. Outsourcing of generic drugs offers notable benefits when its manufacturing is done to supply to multiple customers (parent generic organization) with the same active pharmaceutical ingredient (API). Moreover, rising patent expiries and increasing preference of originator product manufacturing firms for contract research organizations to conduct clinical research is expected to show growth within the API small molecule segment for generics manufacturing. However, regulatory concerns related to contract manufacturing processes are expected to restrict the contract pharmaceutical manufacturing market growth in the near future. Moreover, rising number of FDA inspections of foreign manufacturing facilities is uncovering more violative operations. The U.S. Food and Drug Administration (FDA) issues regulatory notices regarding violative production practices and inadequate quality control to CROs and CMOs. For instance, in November 2016, Dr. Reddy’s Laboratories received a warning letter from the FDA. The warning letter covered two facilities, which manufacture APIs at Srikakulam (Andhra Pradesh) and Miryalaguda (Telangana), and a cancer product manufacturing facility at Duvvada (AP) in India. To avoid the FDA warning or further casualties, manufacturers are required to ensure that its drugs are produced in accordance to FDA’s regulations ensuring product safety, identity, strength, quality, and purity. Geographically, Asia Pacific is expected to offer conducive environment for growth in the contract pharmaceutical manufacturing market, owing to expanding healthcare infrastructure, lower operational cost of clinical trial, research, and manufacturing, and availability of skilled scientific manpower. Furthermore, outsourcing of administrative process of research and manufacturing, to companies in emerging economies, especially BRIC (Brazil, Russia, India, and China) can substantially reduce time required to conduct clinical research and manufacturing and also reduce economic expenses. Furthermore, outsourcing in this region often offers access to a larger number of patients with quicker enrollment and in general, a shorter trial timeline from start to finish. This will in turn increase adoption of contract pharmaceutical manufacturing services in this region during the forecast period.

  3. Some of the key players operating in the contract pharmaceutical manufacturing market are Accenture plc, Cognizant Technology Solutions, ATOS SE, Catalent, Inc., Covance, Inc., Boehringer Ingelheim GmbH, Genpact Limited, Lonza Group, PAREXEL International Corporation, Quintiles Transnational Corporation, Abbvie, Inc., Baxter International Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd. and Piramal Enterprises Ltd. Report includes chapters which deeply display the following deliverable about industry : • Contract Pharmaceutical Manufacturing Market Research Objective and Assumption • Contract Pharmaceutical Manufacturing Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Contract Pharmaceutical Manufacturing Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Contract Pharmaceutical Manufacturing Market, By Regions • Contract Pharmaceutical Manufacturing Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Contract Pharmaceutical Manufacturing Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Contract Pharmaceutical Manufacturing Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Contract Pharmaceutical Manufacturing Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Some of the key players operating in the contract pharmaceutical manufacturing market are Accenture plc, Cognizant Technology Solutions, ATOS SE, Catalent, Inc., Covance, Inc., Boehringer Ingelheim GmbH, Genpact Limited, Lonza Group, PAREXEL International Corporation, Quintiles Transnational Corporation, Abbvie, Inc., Baxter International Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd. and Piramal Enterprises Ltd.

  4. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2397 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related